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https://doi.org/10.1016/j.ccell.2019.01.002SUMMARYThe high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an
attractive target for immunotherapy. We generated chimeric antigen receptor (CAR) T cells targeting B7-H3
(B7-H3.CAR-Ts) and found that B7-H3.CAR-Ts controlled the growth of pancreatic ductal adenocarcinoma,
ovarian cancer and neuroblastoma in vitro and in orthotopic and metastatic xenograft mouse models, which
included patient-derived xenograft. We also found that 4-1BB co-stimulation promotes lower PD-1 expres-
sion in B7-H3.CAR-Ts, and superior antitumor activity when targeting tumor cells that constitutively ex-
pressed PD-L1. We took advantage of the cross-reactivity of the B7-H3.CAR with murine B7-H3, and found
that B7-H3.CAR-Ts significantly controlled tumor growth in a syngeneic tumor model without evident
toxicity. These findings support the clinical development of B7-H3.CAR-Ts.INTRODUCTION
Remarkable clinical responses have been reported in B cell ma-
lignancies treated by the adoptive transfer of T cells redirected
with a chimeric antigen receptor (CAR) specific for CD19 (Brent-
jens et al., 2013; Maude et al., 2014). However, developing CAR-
Ts for the treatment of solid tumors is challenging becauseSignificance
Wedeveloped CAR-Ts for targeting B7-H3 in solid tumors, whic
topic, metastatic, and patient-derived xenograft mouse model
expression of B7-H3 in solid tumors, B7-H3.CAR-Ts may provid
lenging to treat. Furthermore, we found that 4-1BB co-stimulatio
to their superior antitumor activity when targeting pancreatic tu
provides further guidelines for the selection of appropriate co-santigens expressed on the cell surface of tumor cells are gener-
ally shared with some normal tissues, often intratumorly hetero-
geneous, and not broadly expressed across different tumor
types (Newick et al., 2017).
B7-H3 is a type I transmembrane protein that belongs to the
B7 immune co-stimulatory and co-inhibitory family and has
two isoforms in humans, 2Ig-B7-H3 and 4Ig-B7H3, and oneh effectively controlled tumor cell growth in vitro and in ortho-
s without causing detectable toxicity. Considering the broad
e therapeutic opportunities for cancer patients who are chal-
n promotes lower PD-1 expression in B7-H3.CAR-Ts, leading
mor cells that constitutively expressed PD-L1. This evidence






Figure 1. B7-H3.CAR-Ts Target B7-H3+ PDAC Cells
(A) Representativemicrographs of B7-H3 expression in PDAC assessed by staining with the 376.96mAb at the final concentration of 1 mg/mL. Slides stained only
with the secondary Ab were used as a negative control. Scale bars, 200 mm.
isoform in mice, 2Ig-B7-H3, that shares 88% amino acid identity
with the human 2Ig-B7-H3 isoform (Chapoval et al., 2001; Stein-
berger et al., 2004). B7-H3 has immune inhibitory functions. It
reduces type I interferon (IFN) released by T cells and cytotoxic
activity of natural killer cells (Lee et al., 2017). Other studies sup-
port a negative immune regulatory role of B7-H3 in models of
graft-versus-host disease, cardiac allograft rejection, airway
inflammation, and autoimmune encephalomyelitis (Leitner
et al., 2009; Prasad et al., 2004; Suh et al., 2003; Ueno et al.,
2012; Veenstra et al., 2015; Vigdorovich et al., 2013). Conversely,
B7-H3 has also been described as a T cell co-stimulatory mole-
cule in vitro and in autoimmune disease models (Chapoval et al.,
2001; Chen et al., 2012).
The B7-H3 protein has limited expression in normal human
tissues, such as prostate, breast, placenta, liver, colon, and
lymphoid organs (Hofmeyer et al., 2008; Seaman et al., 2017).
However, it is aberrantly expressed in a high proportion of human
malignancies (Inamura et al., 2017; Loos et al., 2010; Picarda
et al., 2016; Seaman et al., 2017; Yamato et al., 2009). In addi-
tion, B7-H3 is found to be overexpressed by the tumor-associ-
ated vasculature and stroma fibroblasts (Inamura et al., 2017;
Seaman et al., 2017). Overexpression of B7-H3 in tumor cells
frequently correlates with fewer tumor-infiltrating lymphocytes,
faster cancer progression, and poor clinical outcome in several
malignancies, such as pancreatic ductal adenocarcinoma
(PDAC), prostate cancer, ovarian cancer (OC), lung cancer,
and clear cell renal carcinoma (Benzon et al., 2017; Inamura
et al., 2017; Loos et al., 2009, 2010; Parker et al., 2011; Picarda
et al., 2016; Qin et al., 2013; Roth et al., 2007; Yamato et al.,
2009; Zang et al., 2007, 2010). Due to its broad expression
across multiple tumor types, B7-H3 is an attractive target for
cancer immunotherapy. B7-H3-specific monoclonal antibodies
(mAbs) and antibody-drug conjugates showed antitumor
activity against B7-H3+ tumor cells in xenograft mouse models,
and phase I clinical trials showed a good safety profile
(NCT01099644, NCT02381314 and NCT02982941) (Fauci
et al., 2014; Kasten et al., 2017; Kramer et al., 2010; Loo et al.,
2012; Seaman et al., 2017; Souweidane et al., 2018).
Here we aimed to systematically examine the safety and anti-
tumor activity of T cells expressing a B7-H3-specific CAR.
RESULTS
PDAC Expresses B7-H3 and Is Targeted by
B7-H3.CAR-Ts
Frozen human PDAC specimens were cryosectioned and
stained with the B7-H3 mAb 376.96. As shown in Figure 1A,(B) Expression of B7-H3 in five human PDAC cell lines stained with the 376.96 m
(C andD) PDAC cell lines labeledwith GFPwere co-culturedwith NT, B7-H3.CAR-
PDAC (GFP+) and B7-H3.CAR-Ts (CD3+) were enumerated by flow cytometry. Re
(D) are illustrated (n = 4). Error bars denote SD.
(E and F) Summary of IFN-g (E) and IL-2 (F) released by NT, B7-H3.CAR-28z-Ts, a
the indicated cell lines as measured by ELISA (n = 4). Error bars denote SD.
(G) The Raji cell line was engineered to express h4Ig-B7-H3 via retroviral gene tra
single clones were expanded. B7-H3 expression of the clones was assessed by
(H and I) Representative flow-cytometry plots of Raji cells (CD4CD8) and T cells
type (WT) and Raji 4Ig-B7-H3 clones were co-cultured with NT, CD19.CAR-Ts, B7
SD; **p < 0.01, one-way ANOVA with Holm-Sidak test adjusted p value.
See also Figure S1.PDAC stained strongly positive for B7-H3, with the antigen ex-
pressed by both tumor cells and surrounding stroma (Figures
S1A–S1C). We generated a B7-H3.CAR using the single-chain
variable fragment (scFv) derived from the B7-H3 376.96 mAb
(Fauci et al., 2014; Imai et al., 1982; Kasten et al., 2017) and
included either CD28 or 4-1BB endodomains (B7-H3.CAR-28z
and B7-H3.CAR-BBz, respectively) (Figure S1D). The transduc-
tion efficiency of activated T cells was generally greater than
60%, and phenotypic analysis showed that B7-H3.CAR-Ts con-
tained central-memory, effector-memory, and T stem cell mem-
ory, without significant differences between CD28 and 4-1BB
co-stimulation (Figures S1E–S1I). B7-H3.CAR-Ts specifically
recognized tumor cells expressing either the 2Ig-B7-H3 or 4Ig-
B7-H3 isoform of human B7-H3 (Figures S1J–S1N). The
antitumor activity of B7-H3.CAR-Ts was evaluated against five
human PDAC cell lines (Panc-1, BxPC-3, Panc-10.05, Capan-1,
and AsPC-1) that express B7-H3 (Figure 1B). PDAC cell lines
were co-cultured with control non-transduced T cell (NT), B7-
H3.CAR-28z-Ts, and B7-H3.CAR-BBz-Ts at different T cell to tu-
mor cell ratios. As shown in Figures 1C and 1D, B7-H3.CAR-Ts
effectively controlled PDAC cell growth even at the T cell to tu-
mor cell ratio of 1 to 5. Cytolytic activity of B7-H3.CAR-Ts was
corroborated by cytokine release (IFN-g and interleukin-2
[IL-2]) in the culture supernatant (Figures 1E and 1F), and by
T cell proliferation in response to B7-H3+ target cells, as as-
sessed by carboxyfluorescein diacetate succinimidyl ester
(CFSE) dilution assay (Figure S1O). We also assessed how the
density of B7-H3 expression in target cells affects the antitumor
activity of B7-H3.CAR-Ts by generating single-cell clones of
tumor cells expressing different levels of the human 4Ig-B7-H3
isoform (Figure 1G). Tumor cells expressing low levels of 4Ig-
B7-H3, triggered significantly less activity of B7-H3.CAR-Ts
even when T cells were cultured with tumor cells at the high
T cell to tumor cell ratio of 1 to 1 (Figures 1H and 1I).
B7-H3.CAR-Ts Show Antitumor Activity in PDAC
Xenograft Models
To evaluate the antitumor effects of B7-H3.CAR-Ts in vivo, we im-
planted the FFluc-transduced Panc-1 tumor cell line into the
pancreas of NOD/SCID/gamma(c) (null) (NSG) mice. Twelve
days later, mice were infused with CD19.CAR-Ts, B7-H3.CAR-
28z-Ts, and B7-H3.CAR-BBz-Ts intravenously (i.v.) via tail vein
injection, when the median bioluminescence intensity (BLI) of
the tumors was 1.5 ± 1.5 3 109 (Figure 2A). Both B7-H3.CAR-
28z-Ts and B7-H3.CAR-BBz-Ts effectively controlled Panc-1 tu-
mor cell growth, and mice remained tumor free for up to
80 days post treatment, while the tumor grew in mice treatedAb as assessed by flow cytometry.
28z-Ts, or B7-H3.CAR-BBz-Ts at the T cell to tumor cell ratio of 1 to 5. On day 5,
presentative flow-cytometry plots (C) and quantification of residual tumor cells
nd B7-H3.CAR-BBz-Ts in the culture supernatant after 24 h of co-culture with
nsfer. Cells were sorted based on different expression level of 4Ig-B7-H3, and
staining with the 376.96 mAb and analyzed by flow cytometry.
(CD4+ or CD8+) (H) and summary of residual tumor cells (I) 5 days after Raji wild-
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Figure 2. B7-H3.CAR-Ts Control PDAC Growth in Xenograft Models
(A) Schema of the PDAC orthotopic xenograft model infused with CAR-Ts on day 12 after tumor inoculation.
(B) Representative bioluminescence images of FFluc-Panc-1 tumor growth in the PDAC orthotopic model shown in (A).
(legend continued on next page)
with control T cells (Figures 2B–2D). We also assessed the anti-
tumor activity of B7-H3.CAR-Ts in a PDACmodel with high tumor
burden by delaying the infusion of T cells until day 28 post tumor
injection, when the median BLI of the tumors was 2.7 ± 1.33 1010
(Figure 2E). Both B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts
effectively controlled the tumor growth (Figures 2F and 2G). To
further investigate the efficacy of B7-H3.CAR-Ts, we imple-
mented a metastatic PDAC model by infusing Panc-1 tumor cells
i.v. into NSGmice (Figure 2H). As shown in Figures 2I and 2J, B7-
H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts, but not CD19.CAR-Ts,
controlled Panc-1 tumor growth up to day 70post treatmentwhen
the experiment was terminated. Overall, B7-H3.CAR-28z-Ts and
B7-H3.CAR-BBz-Ts showed comparable antitumor properties in
Panc-1 orthotopic and metastatic PDAC models, and CAR-Ts
persisted for up to 70 days post infusion (Figure 2K).
B7-H3.CAR-Ts Show Antitumor Activity in PDAC
Patient-Derived Xenografts
PDAC patient-derived xenograft (PDAC-PDX) tumor models
allow faithful recapitulation of histology, genetics, and transcrip-
tome to the donor patient-derived tumor (Siolas and Hannon,
2013). We analyzed B7-H3 expression in early passages of three
primary PDAC cell lines established from ascites of three
patients (PDAC-2, PDAC-3, and PDAC-6) (Figure 3A), and co-
cultured them with NT, B7-H3.CAR-28z-Ts, or B7-H3.CAR-
BBz-Ts at T cell to tumor cell ratios of 1 to 5 and 1 to 10. As
shown in Figures 3B–3D, both B7-H3.CAR-28z-Ts and B7-
H3.CAR-BBz-Ts effectively eliminated PDAC cells from the co-
culture. Cytolytic activity was corroborated by cytokine release
(IFN-g and IL-2) in the culture supernatant (Figures 3E and 3F),
and by antigen-specific T cell proliferation as assessed by
CFSE dilution assay (Figure 3G). PDAC-PDX tumor fragments
were orthotopically implanted into the pancreas of NSG mice.
We confirmed that PDAC-PDX retained the expression of
B7-H3 in vivo upon engraftment in NSG mice (Figure 3H). Three
weeks post PDAC-PDX tumor implantation, mice received
CD19.CAR-Ts, B7-H3.CAR-28z-Ts, or B7-H3.CAR-BBz-Ts i.v..
In the first PDAC-PDX model both B7-H3.CAR-28z-Ts and
B7-H3.CAR-BBz-Ts controlled tumor growth and eliminated
the tumor in 2 of 5mice in both groups by day 31 upon T cell infu-
sion when the experiment was terminated because mice treated
with CD19.CAR-Ts developed signs of graft-versus-mouse dis-
ease characterized by weight and fur loss and lethargy (Figures
3I and 3J). In the second PDAC-PDX model, a sustained anti-
tumor effect (>80 days) was observed without occurrence of
graft-versus-mouse disease (Figure 3K).(C) Representative ultrasound imaging measurement of the FFluc-Panc-1 tumor
PDAC orthotopic model shown in (A). The arrow indicates the tumor. Dimension
(D) Bioluminescence kinetics of FFluc-Panc-1 tumor growth (5 mice/group) in th
(E) Schema of the PDAC orthotopic xenograft model infused with CAR-Ts on da
(F and G) Representative bioluminescence images (F) and bioluminescence kine
model in (E).
(H) Schema of the PDAC metastatic model.
(I and J) Representative bioluminescence images (I) and bioluminescence
(5 mice/group) in (H).
(K) T cells in the blood, spleen, and bone marrow from mice in the PDAC metasta
expression of CD45 and CD3 by flow cytometry (5 mice/group).
Days indicated in (B), (F), and (I) represent days post T cell infusion. The horizon
chi-square test.B7-H3.CAR-Ts Expressing 4-1BB Have Low Expression
of PD-1 and Superior Antitumor Activity when Targeting
PDAC Constitutively Expressing PD-L1
In the xenograft models using the Panc-1 PDAC cell line,
B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts showed compara-
ble antitumor activity. To assess whether CD28 versus 4-1BB
co-stimulation may have a different outcome in tumor rechal-
lenge experiments, mice that cleared Panc-1 PDAC tumor cells
upon infusion of B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts
were rechallenged with tumor cells (Figure 4A). Both
B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts had comparable
and sustained antitumor activity (Figures 4B and 4C) without
showing significant differences inmemory T cell subsets (Figures
S2A–S2D). By contrast, circulating B7-H3.CAR-BBz-Ts were
numerically more abundant than B7-H3.CAR-28z-Ts (Figures
4D–4F) and showed lower expression of PD-1 in CD8+ T cells,
but not in CD4+ T cells (Figures 4G–4I and S2E). At later time
points, B7-H3.CAR-BBz-Ts also showed lower TIM3 expression
(Figures S2F and S2G). The lower expression of PD-1 in
B7-H3.CAR-BBz-Ts was confirmed in vitro when B7-H3.CAR-
28z-Ts and B7-H3.CAR-BBz-Ts were co-cultured with B7-H3+
target cells (Figures 4J and S2H), indicating that B7-H3.CAR-
BBz-Ts could be less susceptible to PD-L1 mediated inhibition.
We stressed the in vitro co-culture conditions by co-culturing
B7-H3.CAR-Ts with three PD-L1-negative (Panc-1, Capan-1,
and AsPC-1) and two PD-L1-positive (BxPC-3 and Panc-10.05)
PDAC cells lines at very low T cell to tumor cell ratio (1 to 10). In
these conditions, B7-H3.CAR-BBz-Ts showed a trend for better
tumor elimination against the two PD-L1+ PDAC tumor cell lines
(Figures S2I and S2J). The superior antitumor activity of B7-
H3.CAR-BBz-Ts versus B7-H3.CAR-28z-Ts in the presence of
PD-L1 was more evident in vivo in mice engrafted with the
PD-L1+ BxPC-3 tumor cell line (Figures 4K–4M).
B7-H3.CAR-Ts Show Effective Antitumor Activity in
Ovarian Cancer and Neuroblastoma Xenograft Models
Since B7-H3 is broadly expressed in multiple solid tumors, we
investigated the antitumor effects of B7-H3.CAR-Ts in ovarian
cancer (OC) and neuroblastoma (NB) models. Eighteen cryosec-
tionedOC specimensmounted in a tumormicroarray (TMA)were
analyzed for the expression of B7-H3, and 90% stained positive
with the 376.96 mAb on both tumor cells and stroma (Figures 5A
and S3A–S3D). Three human OC cell lines (SW626, SK-OV-3,
and CaoV-3) that expressed B7-H3 (Figure 5B) were co-cultured
with NT, B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts at T cell to
tumor cell ratio of 1 to 5. As shown in Figures 5C–5E, bothon day 50 after tumor implantation in mice treated with CD19.CAR-Ts in the
s of the tumor were 6.85 3 5.85 mm.
e PDAC orthotopic model in (A).
y 28 after tumor inoculation.
tics (G) of FFluc-Panc-1 tumor growth (5 mice/group) in the PDAC orthotopic
kinetics (J) of FFluc-Panc-1 cell growth in the PDAC metastatic model
tic model in (H) euthanized 70 days after CAR-T infusion were identified by the
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Figure 3. B7-H3.CAR-Ts Target Patient-Derived PDAC In Vitro and In Vivo
(A) Representative flow plots showing B7-H3 expression in early passages of three primary PDAC cell lines established from ascites of three PDAC patients and
stained with the 376.96 mAb.
(B) The primary PDAC cell lineswere labeledwithGFP and co-culturedwith NT, B7-H3.CAR-28z-Ts, or B7-H3.CAR-BBz-Ts at the T cell to PDAC ratio of 1 to 5. On
day 5, tumor cells (GFP+) and T cells (CD3+) were enumerated by flow cytometry.
(C and D) Summary of residual tumor cells after the co-culture of NT, B7-H3.CAR-28z-Ts, and B7-H3.CAR-BBz-Ts with the primary PDAC cell lines at T cell to
tumor cell ratios of 1 to 5 (C) (on day 5, n = 6) and of 1 to 10 (D) (on day 7, n = 4). Error bars denote SD.
(E and F) Summary of IFN-g (E) and IL-2 (F) released in the culture supernatant by NT, B7-H3.CAR-28z-Ts, and B7-H3.CAR-BBz-Ts after 24 h of co-culture with
the primary PDAC cell lines as measured by ELISA (n = 4). Error bars denote SD.
(G) CFSE dilution of CFSE-labeled B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts co-cultured with the primary PDAC cell lines for 5 days at 1 to 1 ratio analyzed by
flow cytometry. CFSE-labeled T cells alone were used as control.
(H) Representative micrographs of B7-H3 expression in PDAC-PDX engrafted into the pancreas of NSG mice assessed by staining with the 376.96 mAb at the
final concentration of 1 mg/mL. Slides stained only with the secondary Ab were used as a negative control. Scale bars, 200 mm.
(I–K) Representative ultrasound images of tumors (dotted circles marked the tumors) (I) and summary of the tumor volumes measured by ultrasound imaging in










Figure 4. 4-1BB Co-stimulation Promotes Low Expression of PD-1 and Better Antitumor Activity against PDAC Tumor Cells Constitutively
Expressing PD-L1
(A) Schema of the Panc-1 tumor rechallenge model in which mice were rechallenged with tumor cells at days 28, 49, and 63 after CAR-Ts infusion.
(B and C) Representative bioluminescence images (B) and bioluminescence kinetics (C) of the FFluc-Panc-1 tumor growth in the model shown in (A)
(5 mice/group).
(legend continued on next page)
B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts effectively
controlled the growth of OC cell lines and released cytokines in
the culture supernatant. For the in vivo validation, the FFluc-
transduced SK-OV-3 tumor cell line was inoculated intraperito-
neally (i.p.) into NSGmice to create an i.p. OCmodel. Twoweeks
after tumor injection, mice received CD19.CAR-Ts, B7-H3.CAR-
28z-Ts, or B7-H3.CAR-BBz-Ts i.p. since this type of CAR-T
delivery is currently considered in clinical trials (NCT02498912).
As shown in Figures 5F–5H, B7-H3.CAR-Ts significantly
controlled tumor growth and extended the overall survival. Anti-
tumor activity of B7-H3.CAR-Ts was also observed when T cells
were infused i.v. (Figures S3E–S3G), although the i.p. inoculation
was more effective.
We then assessed the effects of B7-H3.CAR-Ts in NB. The
cryosectioned human NB sample positively stained with the
376.96 mAb, as did four human NB cell lines (CHLA-255, IMR-
32, LAN-1, and SKNLP) (Figures 5I and 5J). NB tumor cell lines
were co-cultured with NT, B7-H3.CAR-28z-Ts, or B7-H3.CAR-
BBz-Ts at T cell to tumor cell ratio of 1 to 5. As shown in Fig-
ure 5K, B7-H3.CAR-Ts effectively controlled tumor cell growth.
Cytolytic activity was corroborated by cytokine release in the
co-culture supernatant (Figures 5L and 5M). FFluc-transduced
CHLA-255 tumor cells were infused i.v. into NSG mice to
generate a metastatic NB model. To assess the dose effect
of B7-H3.CAR-Ts, we infused two different doses of B7-
H3.CAR-28z-Ts (2 3 106 and 5 3 106 cells/mouse) i.v. 2 weeks
after tumor inoculation. B7-H3.CAR-28z-Ts controlled tumor
growth compared with mice treated with CD19.CAR-Ts, and
the highest dose of T cells eliminated the tumor for more than
90 days (Figures 5N–5P).
B7-H3.CAR-Ts Control Tumor Growth in
Immunocompetent Mice without Causing Toxicity
We assessed the expression of B7-H3 in cryosectioned normal
human TMA using the 376.96 mAb from which the B7-H3.CAR
was derived. Slides were analyzed blindly by an experienced
pathologist (K.G.). Major organs such as heart, brain, lung, kid-
ney, and muscle are B7-H3 negative, while focal, weak to mod-
erate B7-H3-positive staining was observed in the cytoplasm of
some normal human tissues (Figure 6 and Table S1). The highest
expression was observed in the stomach, with moderate to
strong staining of gastric epithelium, adrenal gland with weak
to moderate cytoplasmic staining, and salivary gland with mod-
erate to strong cytoplasmic staining of acinar epithelium. To
develop a murine model to assess the potential toxicity of
B7-H3.CAR-Ts, we evaluated whether the 376.96mAb cross-re-
acts with murine B7-H3 (mB7-H3). As shown in Figure S4A, hu-
man Raji cells engineered to express mB7-H3 were positively
stained by the 376.96 mAb, indicating cross-recognition of(D–I) Circulating CAR-Ts (CD45+CD3+) (D–F) and PD-1 expression in CAR-Ts (G–I)
infusion were examined by flow cytometry (n = 5). *p < 0.05, **p < 0.01, unpaired
(J) PD-1 expression in B7-H3.CAR-28z-Ts and B7-H3.CAR-BBz-Ts co-cultured w
daily from day 1 to day 7 (n = 8). Error bars denote SD; *p < 0.05, ***p < 0.001, unpa
(K and L) NSG mice were engrafted with the FFluc-BxPC-3 PDAC tumor cell line
tumor inoculation. Representative bioluminescence (K) and bioluminescence kin
(M) Kaplan-Meier survival curve of mice in (K) (5 mice/group), *p = 0.0158 (B7
B7-H3.CAR-28z), chi-square test. In this model for the survival curve, mice were
Days indicated in (B) and (K) represent the days post T cell infusion. The horizonmB7-H3 by the 376.96 mAb. mB7-H3 expressing Raji cells
were eliminated by B7-H3.CAR-Ts and CD19.CAR-Ts in co-cul-
ture experiments (Figures S4B and S4C). In addition, B7-
H3.CAR-Ts and CD19.CAR-Ts released a comparable level of
IFN-g and IL-2 (Figures S4D and S4E), which demonstrates
that B7-H3.CAR-Ts and CD19.CAR-Ts show similar activation
when targetingmB7-H3 expressing Raji cells. We alsomeasured
directly the binding affinity of the 376.96 mAb to both human and
murine B7-H3 proteins (Figures S4F and S4G). Even if the bind-
ing affinity tomB7-H3 is lower comparedwith h2Ig-B7-H3, which
is the human isoform closest to mB7-H3, B7-H3.CAR-Ts still
released a significant amount of IFN-g in response to 50 nM of
mB7-H3 protein (Figure S4H), indicating that an immunocompe-
tent murine model may be informative concerning potential toxic
effects of B7-H3.CAR-Ts. We generated a murine version of the
B7-H3.CAR by using the same scFv derived from the 376.96
mAb and replacing human signaling molecules with the murine
CD28 and CD3z (mB7-H3.CAR) (Figure S4I). Activated murine
T cells were then transduced with this vector to express the
CARs (Figures S4J–S4L). A murine version of the mCD19-spe-
cific CAR was used as a control (mCD19.CAR) (Kochenderfer
et al., 2010). mB7-H3.CAR-Ts specifically targeted the murine
PDAC cell line KPC-4662 engineered to express mB7-H3 (Fig-
ures 7A–7D), and released cytokines (Figures 7E and 7F). To
ensure that the 376.96 mAb cross-reacts with the mB7-H3
endogenously expressed by murine cells, we evaluated the
expression of B7-H3 in bone marrow-derived dendritic cells
(BMDCs) generated from C57BL/6J mice (Lee et al., 2017; Pra-
sad et al., 2004). While non-activated BMDCs had undetectable
B7-H3 expression, activation with lipopolysaccharide (LPS)
induced B7-H3 expression that was detected at comparable
levels when the cells were stained with either the 376.96 mAb
or another murine specific B7-H3mAb (Seaman et al., 2017) (Fig-
ure 7G). To test whether LPS-activated BMDCs are targetable by
mB7-H3.CAR-Ts, we co-cultured LPS-activated BMDCs with
syngeneic NT, mCD19.CAR-Ts or mB-H3.CAR-Ts at 1 to 1 ratio.
As shown in Figure 7H, we observed very low or undetectable
IFN-g release by mB7-H3.CAR-Ts in response to activated
BMDCs. We also assessed the expression of mB7-H3 in normal
murine tissues and observed a similar distribution of B7-H3 as in
human tissues (Figure S5 and Table S2). To investigate the po-
tential toxicities of mB7-H3.CAR-Ts in immunocompetent
mice, we irradiated non-tumor-bearing 6-week-old C57BL/6J
mice with 400 cGy, to create a lymphodepleted environment
that favors the expansion of adoptively transferred T cells, and
then infused them i.v. with syngeneic control NT, mCD19.CAR-
Ts, or mB7-H3.CAR-Ts 2 days later. Five days after T cell
infusion, mice receiving mCD19.CAR-Ts showed B cell deple-
tion while no significant changes in blood cell counts and in mice 22 days (D and G), 48 days (E and H), and 63 days (F and I) after CAR-Ts 
 and non-parametric Mann-Whitney test with two-tailed p value calculation.
ith 2Ig-B7-H3+ Raji cells at the T cell to tumor cell ratio of 1 to 1 was analyzed 
ired and non-parametric Mann-Whitney test with two-tailed p value calculation.
 that constitutively expresses PD-L1 and infused with CAR-Ts on day 14 after 
etics (L) of the FFluc-BxPC-3 PDAC tumor cell line (5 mice/group).
-H3.CAR-28z versus B7-H3.CAR-BBz), **p = 0.0039 (CD19.CAR-28z versus 
 censored when the luciferase signal reached 3.5 3 109 photons per second. 













Figure 5. B7-H3.CAR-Ts Target B7-H3+ OC and NB Cancer Cells Both In Vitro and In Vivo
(A) Representative micrographs of B7-H3 expression in normal ovary and OC assessed by staining with the 376.96 mAb at the final concentration of 1 mg/mL.
Scale bars, 200 mm.
(legend continued on next page)
composition were observed in mice receiving mB7-H3.CAR-Ts
(Figures S6A and S6B). As clinical studies with adoptive transfer
of CAR-Ts suggest that the maximal expansion mediated by
CD28 co-stimulation and potentially lethal toxic effects occur
within 2–3 weeks post T cell infusion (Brentjens et al., 2013),
mice were monitored for the ensuing 2 weeks and then eutha-
nized to assess organ toxicities. At the time of euthanasia, all
mice were alive and healthy. Mice treated with mCD19.CAR-Ts
showed persistent B cell depletion in blood, spleen, and bone
marrow while mice treated with mB7-H3.CAR-Ts did not show
any decrease in cell counts (Figures 7I–7K). Similarly, no evident
lesions or aberrant T lymphocyte infiltration were observed in tis-
sue sections (Figure S7 and Table S3). To rule out any effect due
to the irradiation of the mice before the infusion of CAR-Ts, we
also infused C57BL/6J mice with mB7-H3.CAR-Ts without irra-
diation. Mice euthanized and analyzed at day 11 after T cell infu-
sion did not show evident signs of toxicity (Figures S6C–S6E).
We further evaluated the effects of mB7-H3.CAR-Ts in tumor-
bearing mice. In brief, 6-week-old C57BL/6J mice were ortho-
topically engrafted in the pancreas with the murine PDAC tumor
cell line KPC-4662 modified to express mB7-H3. Seventeen
days later, mice were irradiated with 400 cGy and then infused
i.v. with syngeneic control NT or mB7-H3.CAR-Ts 2 days later
(Figure 8A). As shown in Figures 8B and 8C, mB7-H3.CAR-Ts
controlled tumor growth for 4 weeks as assessed by ultrasound
measurement and tumor weight. When euthanized at days 33 –
34, 2 of 5 control mice showed liver metastases in addition to the
primary pancreatic tumor, while liver metastases were not
observed in mB7-H3.CAR-Ts-treated mice. At the time of eutha-
nasia, in mice with tumor we did observe a slight increase of
T cell infiltration and PD-1 expression at the tumor site in mB7-
H3.CAR-Ts-treated group compared with control mice (Figures
S8A–S8D). Themolecular signal of mB7-H3.CARwas detectable
in the spleen and tumor collected frommB7-H3.CAR-Ts-treated
mice but not in control mice (Figures 8D and 8E). Mice treated
with mB7-H3.CAR-Ts did not show any significant decrease of
hematopoietic cell or immune cell counts in blood, spleen,
bone marrow, and lymph nodes, except for the decrease in
monocyte counts in the peripheral blood (Figures 8F, 8G, S8E,(B) Expression of B7-H3 in three human OC cell lines assessed by flow cytometr
(C) Summary of residual tumor cells in the culture on day 5 of co-culture of NT, B7
cell ratio of 1 to 5 (n = 5). Error bars denote SD.
(D and E) Summary of IFN-g (D) and IL-2 (E) released by NT, B7-H3.CAR-28z-Ts,
measured by ELISA (n = 5). Error bars denote SD.
(F andG) Representative bioluminescence images (F) and bioluminescence kinetic
NSG mice (53 105 cells/mouse) and treatment 14 days later with i.p. inoculation
mouse). Error bars denote SD; ***p < 0.0001, chi-square test.
(H) Kaplan-Meier survival curve of mice developing OC (5 mice/group). **p = 0.0
(I) Representative micrographs of B7-H3 expression in NB assessed by staining w
(J) Expression of B7-H3 in human NB tumor cell lines stained with the 376.96 mA
(K) Summary of residual tumor cells in the culture on day 5 of co-culture of NT, B7
tumor cell ratio of 1 to 5 (n = 8). Error bars denote SD.
(L and M) Summary of IFN-g (L) and IL-2 (M) released by NT, B7-H3.CAR-28z-Ts,
measured by ELISA (n = 8). Error bars denote SD.
(N and O) Representative bioluminescence images (N) and kinetics of the biolu
injection into NSG mice (23 106 cells/mouse) and i.v. infusion with CD19.CAR-Ts
14 days later (5 mice/group). Error bars denote SD; ***p < 0.0001, chi-square tes
(P) Kaplan-Meier survival curve of mice developing metastatic NB (5 mice/group
**p = 0.0018 (B7-H3.CAR-28z 2 3 106 versus 5 3 106 cells/mouse), chi-square t
Days indicated in (F) and (N) represent the days post T cell infusion. See also Figand S8F), and no evident lesions were observed in tissue
sections (Figures 8H and S8G; Table S4). Overall, these results
indicate that B7-H3.CAR-Ts promote tumor control in tumor-
bearing C57BL/6J mice without causing detectable organ
toxicity.
DISCUSSION
We investigated whether B7-H3 is a clinically relevant target for
CAR-T-based immunotherapy in solid tumors. We found that
B7-H3 is aberrantly expressed on the cell surface of PDAC,
OC, and NB, and that B7-H3.CAR-Ts effectively controlled tu-
mor growth in orthotopic and metastatic xenografts and in
PDAC-PDX models. The observed murine-human cross-reac-
tivity of the 376.96 mAb from which the B7-H3.CAR was derived
also allowed us to test the efficacy and safety of B7-H3.CAR-Ts
in an immunocompetent mouse model.
The selection of appropriate target antigens in solid tumors re-
mains challenging for the therapeutic development of safe and
effective CAR-T-based therapies. Toxicities upon the infusion
of CAR-Ts were observed when targeting molecules such as
HER2 or CAIX as these molecules are expressed in some normal
tissues (Lamers et al., 2013, 2016; Morgan et al., 2010). On the
other hand, the therapeutic activity of CAR-Ts can be limited
due to the rapid tumor escape when the targeted antigen shows
heterogeneous expression within the tumor, as recently reported
in patients with glioblastoma treated with CAR-Ts specific for
EGFRvIII (O’Rourke et al., 2017). While the intratumor hetero-
genic expression of the targeted antigen can potentially be
resolved by targeting multiple antigens, toxicities related to
recognition of antigen expressed by normal tissues remains a
major concern. Increasing evidence suggests that intrinsic char-
acteristics of CARmolecules, such as the epitope recognized by
the CAR and the affinity of the mAb from which the CAR is
derived, may play a significant role in discriminating antigen
recognition in normal versus malignant cells. For instance, two
clinical studies targeting HER2 with CAR-Ts derived from two
distinct mAbs showed different safety profiles (Ahmed et al.,
2015, 2017; Morgan et al., 2010). Similarly, different mAbsy after staining with the 376.96 mAb.
-H3.CAR-28z-Ts, and B7-H3.CAR-BBz-Ts with OC cell lines at T cell to tumor
and B7-H3.CAR-BBz-Ts in the co-culture supernatant collected after 24 h and
s (G) of FFluc-SK-OV-3 tumor growth upon intraperitoneal (i.p.) inoculation into
of CD19.CAR-Ts, B7-H3.CAR-28z-Ts, and B7-H3.CAR-BBz-Ts (53 106 cells/
091, chi-square test.
ith the 376.96 mAb at the final concentration of 1 mg/mL. Scale bars, 200 mm.
b and assessed by flow cytometry.
-H3.CAR-28z-Ts, and B7-H3.CAR-BBz-Ts with NB tumor cell lines at T cell to
and B7-H3.CAR-BBz-Ts in the co-culture supernatant collected after 24 h and
minescence (O) of the FFluc-CHLA-255 tumor growth upon intravenous (i.v.)
(53 106 cells/mouse) or B7-H3.CAR-28z-Ts (23 106 or 53 106 cells/mouse)
t.
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Figure 6. Pattern of B7-H3 Expression in Human Normal Tissues
(A and B) Representative micrographs of B7-H3 expression in PDAC (A) and in indicated normal human organs (B) assessed by staining with the 376.96 mAb at
the final concentration of 1 mg/mL. Slides stained only with the secondary Ab were used as a negative control. Black boxes indicate 3-fold zoomed-in cutout.
Micrographs are representative of at least three sections per tissue. Scale bars, 200 mm.
(C) Summary of the positive score of B7-H3 in human normal tissues. Dotted line indicates the background level of the staining. Error bars denote SD.









Figure 7. B7-H3.CAR-Ts Do Not Cause Loss of Cell Subsets in the Blood, Bone Marrow, Spleen, and Lymph Nodes in Immunocompe-
tent Mice
(A) Representative flow plots illustrating mB7-H3 expression in the wild-type (WT) murine PDAC cell line KPC-4662 and the same cell line engineered to express
mB7-H3 via retroviral gene transfer (mB7-H3-Tg). WT and mB7-H3-Tg KPC-4662 cells were stained with the 376.96 mAb.
(B) Representative flow-cytometry plots of WT andmB7-H3-Tg KPC-4662 cells 5 days after co-culture with murine non-transduced T cells (NT), mCD19.CAR-Ts
or mB7-H3.CAR-Ts at T cell to tumor cell ratio of 1 to 2. WT and mB7-H3-Tg KPC-4662 cells were identified by SSC-A and mB7-H3 expression, respectively.
(legend continued on next page)
targeting the same ROR1 antigen, another target evaluated for
CAR-T-based therapy, showed a different pattern of expression
in normal tissues (Balakrishnan et al., 2017; Baskar et al., 2008;
Dave et al., 2012).
Targeting B7-H3 with the B7-H3.CAR derived from the
376.96 mAb addresses critical hurdles to the clinical develop-
ment of CAR-Ts against solid tumors. The 376.96 mAb cap-
tures B7-H3 expression in several human malignancies and
tumor cell lines, recapitulating the high expression of B7-H3
previously reported in solid tumors (Loos et al., 2010; Picarda
et al., 2016). In our experiments, B7-H3.CAR-Ts derived from
the 376.96 mAb showed significant antitumor activity in multi-
ple xenografts of solid tumors, indicating the high potential
for clinical translation of B7-H3.CAR-Ts if these cells do not
cause on-target but off-tumor toxicity. To assess this critical
point, we used the 376.96 mAb to stain normal human tissues
and observed focal cytoplasmic expression on endothelial cells
of normal tissues and areas of high expression in a restricted
array of tissues such as stomach, adrenal gland, and salivary
gland. Other reports showed a similar pattern of B7-H3 expres-
sion in normal tissues using other mAbs (Modak et al., 2001;
Seaman et al., 2017). Our immunohistochemistry analysis of
normal murine tissues also showed a conserved pattern of
B7-H3 expression between human and murine tissues. We
took advantage of the observed cross-reactivity of the 376.96
mAb with murine B7-H3 to perform toxicology and efficacy
studies in immunocompetent mice. We have found control of
tumor growth without modifications of the immune cell and he-
matopoietic cell counts with the exception of monocytes in the
peripheral blood, and no evidence of tissue damage. Despite
the fact that the binding affinity of the 376.96 mAb to mB7-
H3 is inferior to the binding affinity of the human 2IgB7-H3,
the considerable amount of IFN-g released by B7-H3.CAR-Ts
exposed to 50 nM of recombinant mB7-H3 ensures that at least
major toxic effects due to B7-H3.CAR-Ts should be captured in
immunocompetent mice. Our observed lack of on-target off-tu-
mor toxicity of B7-H3.CAR-Ts in immunocompetent mice may
be due to the lower density of mB7-H3 in normal tissues
compared with tumor cells, as illustrated in our experiments us-
ing clones expressing different levels of human B7-H3 and in
murine BMDCs, and as previously reported for other CARs
(Walker et al., 2017). Consistent with our observation, the B7-
H3-specific pyrrolobenzodiazepine-linked m276 mAb showed
antitumor activity in xenograft mouse models targeting both
tumor cells and tumor-associated vasculatures, without overt
toxicity (Fauci et al., 2014; Loo et al., 2012; Seaman et al.,
2017). Although a different expression profile of B7-H3 in mu-(C and D) Summary of residual WT KPC-4662 cells (C) and mB7-H3-Tg KPC-466
ANOVA with Holm-Sidak test adjusted p value.
(E and F) IFN-g (E) and IL-2 (F) released by NT, mCD19.CAR-Ts, and B7-H3.CAR-
Error bars denote SD.
(G) Murine bone marrow-derived dendritic cells (BMDCs) treated without or with 1
mAb, and the expression of mB7-H3 was assessed by flow cytometry.
(H) IFN-g released by NT, mCD19.CAR-Ts, andmB7-H3.CAR-Ts after 24 h of co-c
target cell ratio of 1 to 1 as measured by ELISA (n = 3). Error bars denote SD.
(I–K) C57BL/6mice were irradiated with 400 cGy and 2 days later infused i.v. with s
were euthanized 15 – 16 days post T cell infusion to analyze the immune cell com
mice/group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA
The horizontal bars in (C), (D), and (I) to (K) represent the mean values. See alsorine and human normal tissues remains a possibility, toxicology
studies of an Fc-enhanced B7-H3 Ab carried out in cynomolgus
monkeys also revealed no significant toxicities (Loo et al.,
2012). Furthermore, in a clinical study in which the 131I-conju-
gated B7-H3 Ab was administered to patients with metastatic
NB, no toxicity was encountered (Kramer et al., 2010). Finally,
the clinical translation of B7-H3.CAR-Ts may be further safely
conducted by using either transient expression of the B7-
H3.CAR in T cells as achieved using mRNA electroporation
(Beatty et al., 2014) or by further modifying B7-H3.CAR-Ts to
include the inducible caspase-9 safety switch that provides
an extra safeguard ensuring the rapid elimination of CAR-Ts
in case of toxicities (Di Stasi et al., 2011; Diaconu et al., 2017).
The optimal co-stimulation for CAR-Ts, especially in solid
tumors, remains a matter of significant discussion. It is likely
that CAR co-stimulation needs to be adapted to specific target
antigens, tumor cell type, and tumor microenvironment. In our
study, we systematically compared CD28 with 4-1BB co-stim-
ulation in either orthotopic or metastatic PDAC models. We did
not find significant differences at least in our model using the
Panc-1 PDAC cancer cell line. In particular, phenotypic anal-
ysis in vivo did not show significant differences of effector
versus memory T cells in mice treated with B7-H3.CAR-Ts ex-
pressing CD28 or 4-1BB. However, 4-1BB co-stimulation pre-
served CD8+ T cells with lower expression of PD-1 both in vitro
and in vivo, and when PDAC cell lines constitutively express
PD-L1, B7-H3.CAR-BBz-Ts showed better antitumor activity
compared with B7-H3.CAR-28z-Ts. Finally, the desmoplastic
nature of solid tumors in general and PDAC in particular im-
pairs trafficking, penetration, and survival of CAR-Ts (Newick
et al., 2017). PDAC-PDX tumors are characterized by stroma
fibrosis that mirrors the donor tumor (Tentler et al., 2012).
We tested B7-H3.CAR-Ts in PDAC-PDX models and found
significant antitumor activity, although tumors were not always
eradicated. Furthermore, B7-H3.CAR-Ts controlled PDAC tu-
mor growth in immunocompetent mice, but did not eradicate
the tumor and showed limited persistence within the tumor,
suggesting that the activity of CAR-Ts in solid tumors should
be further augmented using additional T cell engineering and
combination with chemotherapy, irradiation, small molecules,
or other biological agents (Caruana et al., 2015; Dotti
et al., 2014).
In summary, we developed B7-H3.CAR-Ts that control the
tumor growth of PDAC, NB, and OC in xenograft models.
B7-H3.CAR-Ts did not cause evident toxicity in either NSG or
immunocompetent mice, further encouraging their clinical appli-
cation in solid tumors that are difficult to treat.2 cells (D) in the co-culture experiments in (B) (n R 3). ****p < 0.0001, one-way
Ts after 24 h in the co-culture experiments in (B) as measured by ELISA (n = 3).
00 ng/mL LPS for 2 days were stained with the 376.96 mAb or the EPNCIR122
ulture with BMDCs treated without or with 100 ng/mL LPS for 2 days at T cell to
yngeneic NT, mCD19.CAR-Ts, ormB7-H3.CAR-Ts (13 107 cells/mouse). Mice
position of the blood (I), spleen (J), and bone marrow (K) by flow cytometry (5
with Holm-Sidak test adjusted p value.
Figures S4–S7; Tables S2 and S3.
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Figure 8. B7-H3.CAR-Ts Control Tumor Growth in Immunocompetent Mice without Causing Evident Toxicity
(A) Schema of the murine PDAC orthotopic xenograft model.
(B) Summary of the tumor volumemeasured by ultrasound imaging (n = 5 per group). Error bars denote SD; *p = 0.0476 (day 9) and *p = 0.0278 (day 28), unpaired
and non-parametric Mann-Whitney test with two-tailed p value calculation.
(C) Summary of the tumor weight at the end of the experiment (day 33 – 34 after T cell infusion) (n = 5 per group). *p = 0.0157, unpaired and non-parametric Mann-
Whitney test with two-tailed p value calculation.
(D and E) Quantification of mB7-H3.CAR copy numbers by qPCR to evaluate CAR-Ts persistence in the spleens (D) and tumors (E) at the end of the experiment
(day 33 – 34 after T cell infusion).
(F and G) Cell subset composition of the blood (F) and spleens (G) was analyzed by flow cytometry (n = 5 per group). *p = 0.0159, unpaired and non-parametric
Mann-Whitney test with two-tailed p value calculation.
(H) Tissue pathology of the indicated organs was evaluated by H&E staining at the end of the experiment (days 33 – 34 after T cell infusion). Scale bars, 200 mm.
The horizontal bars in (C) to (G) represent the mean values. See also Figure S8 and Table S4.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING
d EXPERIMENTAL MODEL AND SUBJECT DETAILSB Cell Lines and Cell Culture
B Human and Mouse Tissue Samples
B In Vivo Mouse Studies
d METHOD DETAILS
B Plasmid Construction and Retrovirus Production
B Retrovirus Preparation
B Preparation of the 2Ig-B7-H3-GFP Fusion Protein for
the T Cell Staining
B Transduction and Expansion of Human T Cells
B Generation of Murine CAR-T Cells





B Xenogeneic Mouse Models
B Generation of Murine Bone Marrow Derived Dendritic
Cells (BMDCs)
B Evaluate Toxicity of mB7-H3.CAR-Ts in C57BL/6J
Immunocompetent Mice
B Murine PDAC Orthotopic Model in C57BL/6J Mice
B Measurement of the Binding Affinity of the 376.96 mAb
to Human and Murine B7-H3
B Stimulation of B7-H3.CAR-Ts with Plate-Bound B7-
H3-Fc Fusion Proteins
B Measurement of the Copy Numbers of mB7-H3.CAR
d QUANTIFICATION AND STATISTICAL ANALYSISSUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and four tables and can be
found with this article online at https://doi.org/10.1016/j.ccell.2019.01.002.
ACKNOWLEDGMENTS
This work was supported in part by University Cancer Research Fund at
the University of North Carolina at Chapel Hill, United States (G.D.); R01-
CA193140-03 from National Cancer Institute, United States (G.D.); Rivkin
Center for Ovarian Cancer, United States (G.D.); and W81XWH-16-1-
0501 from the Department of Defense, United States (S.F. and G.D.).
S.F. is supported by W81XWH-16-1-0500 from the Department of Defense,
United States; R01DE028172 from National Institute of Dental & Craniofa-
cial Reseacrh, United States, and R03CA223886 from National Cancer
Institute, United States. Histological services are provided by the Histology
Research Core Facility in the Department of Cell Biology and Physiology at
the University of North Carolina at Chapel Hill (UNC). Tissue section service
and immunohistochemistry were provided by the Histology Research Core
Facility in the Department of Cell Biology and Physiology at UNC. Animal
histopathology and clinical services were performed by the Animal Histo-
pathology & Laboratory Medicine Core at UNC, which is supported in
part by an National Cancer Institute Center Core support grant
(5P30CA016086-41), United States, to the UNC Lineberger Comprehensive
Cancer Center (UNC-LCCC). The small animal imaging core and flow cy-
tometry core facilities are supported in part by an National Cancer InstituteCancer core grant (P30-CA016086-40), United States. The frozen human
PDAC specimens were provided by the Tissue Procurement Facility at
UNC-LCCC. We thank Charlene Santos and the Animal Studies Core Facil-
ity for providing mice and surgery service for the PDAC-PDX mouse model.
Finally, we would like to thank Dr. Hongxia Li for her technical support and
Dr. Song Zhang for his critical reading of the manuscript, helpful discus-
sion, and suggestions during revision of the manuscript.
AUTHOR CONTRIBUTIONS
Conceptualization, H.D., K.H., S.A., Y.P.-G., J.J.Y., S.F., B.S., and G.D.; Meth-
odology, H.D., K.H., S.A., N.P.K., S.A.M., K.T., B.M., D.M., S.G.H., Y.X., C.S.,
Y.C., X.M., Y.P.-G., J.J.Y., R.L., B.S., S.F., and G.D.; Investigation, H.D., K.H.,
S.A., N.P.K., S.A.M., K.G., Y.P.-G., J.J.Y., B.S., and G.D.; Writing – Original
Draft, H.D. and G.D.; Writing – Review & Editing, all authors; Resources,
S.G.H., J.J.Y., Y.P.-G., X.W., C.R.F., and S.F.; Supervision, Y.P.-G., J.J.Y.,
S.F., B.S., and G.D.
DECLARATION OF INTERESTS
Drs. Dotti and Savoldo have sponsor research agreements with Bluebird Bio,
Cell Medica, and Bellicum Pharmaceutical. Dr. Dotti serves on the scientific
advisory board of MolMed S.p.A. Drs. Dotti, Ferrone S., Ferrone C.R., and
Du filed a patent for the CAR targeting B7-H3. The other authors declare no
competing interests.
Received: October 17, 2017
Revised: October 31, 2018
Accepted: January 2, 2019
Published: February 11, 2019
REFERENCES
Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D.,
Robertson, C., Gray, T.L., Diouf, O., Wakefield, A., et al. (2017). HER2-specific
chimeric antigen receptor-modified virus-specific T cells for progressive glio-
blastoma: a phase 1 dose-escalation trial. JAMA Oncol. 3, 1094–1101.
Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C.,
Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015). Human epidermal
growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified
T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33,
1688–1696.
Balakrishnan, A., Goodpaster, T., Randolph-Habecker, J., Hoffstrom, B.G.,
Jalikis, F.G., Koch, L.K., Berger, C., Kosasih, P.L., Rajan, A., Sommermeyer,
D., et al. (2017). Analysis of ROR1 protein expression in human cancer and
normal tissues. Clin. Cancer Res. 23, 3061–3071.
Baskar, S., Kwong, K.Y., Hofer, T., Levy, J.M., Kennedy, M.G., Lee, E., Staudt,
L.M., Wilson, W.H., Wiestner, A., and Rader, C. (2008). Unique cell surface
expression of receptor tyrosine kinase ROR1 in human B-cell chronic lympho-
cytic leukemia. Clin. Cancer Res. 14, 396–404.
Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., and
Vonderheide, R.H. (2012). Tumor-derived granulocyte-macrophage colony-
stimulating factor regulates myeloid inflammation and T cell immunity in
pancreatic cancer. Cancer Cell 21, 822–835.
Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G.,
Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. (2014). Mesothelin-spe-
cific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor
activity in solid malignancies. Cancer Immunol. Res. 2, 112–120.
Benzon, B., Zhao, S.G., Haffner, M.C., Takhar, M., Erho, N., Yousefi, K.,
Hurley, P., Bishop, J.L., Tosoian, J., Ghabili, K., et al. (2017). Correlation of
B7-H3 with androgen receptor, immune pathways and poor outcome in pros-
tate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis.
20, 28–35.
Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G.,
Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013). CD19-tar-
geted T cells rapidly induce molecular remissions in adults with
chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 
177ra138.
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E.S., Ittmann, 
M.M., Marchetti, D., and Dotti, G. (2015). Heparanase promotes tumor infiltra-
tion and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 
524–529.
Chapoval, A.I., Ni, J., Lau, J.S., Wilcox, R.A., Flies, D.B., Liu, D., Dong, H., Sica, 
G.L., Zhu, G., Tamada, K., et al. (2001). B7-H3: a costimulatory molecule for 
T cell activation and IFN-gamma production. Nat. Immunol. 2, 269–274.
Chen, X., Quinn, E.M., Ni, H., Wang, J., Blankson, S., Redmond, H.P., Wang, 
J.H., and Feng, X. (2012). B7-H3 participates in the development of experi-
mental pneumococcal meningitis by augmentation of the inflammatory 
response via a TLR2-dependent mechanism. J. Immunol. 189, 347–355.
Dave, H., Anver, M.R., Butcher, D.O., Brown, P., Khan, J., Wayne, A.S., 
Baskar, S., and Rader, C. (2012). Restricted cell surface expression of receptor 
tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia 
suggests targetability with therapeutic monoclonal antibodies. PLoS One 7, 
e52655.
Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., 
Straathof, K., Liu, E., Durett, A.G., Grilley, B., et al. (2011). Inducible apoptosis 
as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673–1683.
Diaconu, I., Ballard, B., Zhang, M., Chen, Y., West, J., Dotti, G., and Savoldo, 
B. (2017). Inducible caspase-9 selectively modulates the toxicities of CD19-
specific chimeric antigen receptor-modified T cells. Mol. Ther. 25, 580–592.
Dotti, G., Gottschalk, S., Savoldo, B., and Brenner, M.K. (2014). Design and 
development of therapies using chimeric antigen receptor-expressing 
T cells. Immunol. Rev. 257, 107–126.
Fauci, J.M., Sabbatino, F., Wang, Y., Londono-Joshi, A.I., Straughn, J.M., Jr., 
Landen, C.N., Ferrone, S., and Buchsbaum, D.J. (2014). Monoclonal antibody-
based immunotherapy of ovarian cancer: targeting ovarian cancer cells with 
the B7-H3-specific mAb 376.96. Gynecol. Oncol. 132, 203–210.
Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, 
R.H., Rustgi, A.K., Chang, S., and Tuveson, D.A. (2005). Trp53R172H and 
KrasG12D cooperate to promote chromosomal instability and widely metasta-
tic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483.
Hofmeyer, K.A., Ray, A., and Zang, X. (2008). The contrasting role of B7-H3. 
Proc. Natl. Acad. Sci. U S A 105, 10277–10278.
Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., 
Heslop, H.E., Rooney, C.M., Brenner, M.K., and Dotti, G. (2010). Engineering 
CD19-specific T lymphocytes with interleukin-15 and a suicide gene to 
enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 
1160–1170.
Imai, K., Wilson, B.S., Bigotti, A., Natali, P.G., and Ferrone, S. (1982). A 94,000-
dalton glycoprotein expressed by human melanoma and carcinoma cells. 
J. Natl. Cancer Inst. 68, 761–769.
Inamura, K., Yokouchi, Y., Kobayashi, M., Sakakibara, R., Ninomiya, H., Subat, 
S., Nagano, H., Nomura, K., Okumura, S., Shibutani, T., et al. (2017). Tumor 
B7-H3 (CD276) expression and smoking history in relation to lung adenocarci-
noma prognosis. Lung Cancer 103, 44–51.
Kasten, B.B., Arend, R.C., Katre, A.A., Kim, H., Fan, J., Ferrone, S., Zinn, K.R., 
and Buchsbaum, D.J. (2017). B7-H3-targeted 212Pb radioimmunotherapy of 
ovarian cancer in preclinical models. Nucl. Med. Biol. 47, 23–30.
Kochenderfer, J.N., Yu, Z., Frasheri, D., Restifo, N.P., and Rosenberg, S.A.
(2010). Adoptive transfer of syngeneic T cells transduced with a chimeric 
antigen receptor that recognizes murine CD19 can eradicate lymphoma and 
normal B cells. Blood 116, 3875–3886.
Kramer, K., Kushner, B.H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., 
Zanzonico, P., Humm, J.L., Xu, H., Wolden, S.L., Souweidane, M.M., et al.
(2010). Compartmental intrathecal radioimmunotherapy: results for treatment 
for metastatic CNS neuroblastoma. J. Neurooncol. 97, 409–418.
Lamers, C.H., Klaver, Y., Gratama, J.W., Sleijfer, S., and Debets, R. (2016). 
Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engi-
neered T-cells—a completed study overview. Biochem. Soc. Trans. 44, 
951–959.Lamers, C.H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen,
B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013).
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered
T cells: clinical evaluation and management of on-target toxicity. Mol. Ther.
21, 904–912.
Lee, Y.H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H.J.,
Jeong, M., Chang, S.H., Kim, B.S., et al. (2017). Inhibition of the B7-H3 immune
checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Cell Res. 27, 1034–1045.
Leitner, J., Klauser, C., Pickl, W.F., Stockl, J., Majdic, O., Bardet, A.F., Kreil,
D.P., Dong, C., Yamazaki, T., Zlabinger, G., et al. (2009). B7-H3 is a potent
inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 inter-
action. Eur. J. Immunol. 39, 1754–1764.
Loo, D., Alderson, R.F., Chen, F.Z., Huang, L., Zhang, W., Gorlatov, S., Burke,
S., Ciccarone, V., Li, H., Yang, Y., et al. (2012). Development of an Fc-
enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Clin. Cancer Res. 18, 3834–3845.
Loos, M., Hedderich, D.M., Friess, H., and Kleeff, J. (2010). B7-H3 and its role
in antitumor immunity. Clin. Dev. Immunol. 2010, 683875.
Loos, M., Hedderich, D.M., Ottenhausen, M., Giese, N.A., Laschinger, M.,
Esposito, I., Kleeff, J., and Friess, H. (2009). Expression of the costimulatory
molecule B7-H3 is associated with prolonged survival in human pancreatic
cancer. BMC Cancer 9, 463.
Matheu, M.P., Sen, D., Cahalan, M.D., and Parker, I. (2008). Generation of
bone marrow derived murine dendritic cells for use in 2-photon imaging.
J. Vis. Exp. https://doi.org/10.3791/773.
Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew,
A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. (2014). Chimeric antigen re-
ceptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371,
1507–1517.
Modak, S., Kramer, K., Gultekin, S.H., Guo, H.F., and Cheung, N.K. (2001).
Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by
a wide spectrum of human solid tumors. Cancer Res. 61, 4048–4054.
Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., and
Rosenberg, S.A. (2010). Case report of a serious adverse event following the
administration of T cells transduced with a chimeric antigen receptor recog-
nizing ERBB2. Mol. Ther. 18, 843–851.
Newick, K., O’Brien, S., Moon, E., and Albelda, S.M. (2017). CAR T cell therapy
for solid tumors. Annu. Rev. Med. 68, 139–152.
O’Rourke, D.M., Nasrallah, M.P., Desai, A., Melenhorst, J.J., Mansfield, K.,
Morrissette, J.J.D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A.,
et al. (2017). A single dose of peripherally infused EGFRvIII-directed CAR
T cells mediates antigen loss and induces adaptive resistance in patients
with recurrent glioblastoma. Sci. Transl. Med. 9, https://doi.org/10.1126/sci-
translmed.aaa0984.
Parker, A.S., Heckman, M.G., Sheinin, Y., Wu, K.J., Hilton, T.W., Diehl, N.N.,
Pisansky, T.M., Schild, S.E., Kwon, E.D., and Buskirk, S.J. (2011). Evaluation
of B7-H3 expression as a biomarker of biochemical recurrence after salvage
radiation therapy for recurrent prostate cancer. Int. J. Radiat. Oncol. Biol.
Phys. 79, 1343–1349.
Picarda, E., Ohaegbulam, K.C., and Zang, X. (2016). Molecular pathways: tar-
geting B7-H3 (CD276) for human cancer immunotherapy. Clin. Cancer Res.
22, 3425–3431.
Prasad, D.V., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., and Dong, C.
(2004). Murine B7-H3 is a negative regulator of T cells. J. Immunol. 173,
2500–2506.
Qin, X., Zhang, H., Ye, D., Dai, B., Zhu, Y., and Shi, G. (2013). B7-H3 is a new
cancer-specific endothelial marker in clear cell renal cell carcinoma. Onco
Targets Ther. 6, 1667–1673.
Roth, T.J., Sheinin, Y., Lohse, C.M., Kuntz, S.M., Frigola, X., Inman, B.A.,
Krambeck, A.E., McKenney, M.E., Karnes, R.J., Blute, M.L., et al. (2007).
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis
and potential target for therapy. Cancer Res. 67, 7893–7900.
Seaman, S., Zhu, Z., Saha, S., Zhang, X.M., Yang, M.Y., Hilton, M.B., Morris,
K., Szot, C., Morris, H., Swing, D.A., et al. (2017). Eradication of tumors through
simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vascu-
lature. Cancer Cell 31, 501–515.e8.
Siolas, D., and Hannon, G.J. (2013). Patient-derived tumor xenografts: trans-
forming clinical samples into mouse models. Cancer Res. 73, 5315–5319.
Sohara, Y., Shimada, H., Scadeng, M., Pollack, H., Yamada, S., Ye, W.,
Reynolds, C.P., and DeClerck, Y.A. (2003). Lytic bone lesions in human neuro-
blastoma xenograft involve osteoclast recruitment and are inhibited by
bisphosphonate. Cancer Res. 63, 3026–3031.
Song, L., Asgharzadeh, S., Salo, J., Engell, K., Wu, H.W., Sposto, R., Ara, T.,
Silverman, A.M., DeClerck, Y.A., Seeger, R.C., et al. (2009). Valpha24-invariant
NKT cells mediate antitumor activity via killing of tumor-associated macro-
phages. J. Clin. Invest. 119, 1524–1536.
Souweidane, M.M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S.,
Zanzonico, P., Carrasquillo, J.A., Lyashchenko, S.K., Thakur, S.B., Donzelli,
M., et al. (2018). Convection-enhanced delivery for diffuse intrinsic pontine gli-
oma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 19,
1040–1050.
Steinberger, P., Majdic, O., Derdak, S.V., Pfistershammer, K., Kirchberger, S.,
Klauser, C., Zlabinger, G., Pickl, W.F., Stockl, J., and Knapp, W. (2004).
Molecular characterization of human 4Ig-B7-H3, a member of the B7 family
with four Ig-like domains. J. Immunol. 172, 2352–2359.
Suh, W.K., Gajewska, B.U., Okada, H., Gronski, M.A., Bertram, E.M., Dawicki,
W., Duncan, G.S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003). The B7 family
member B7-H3 preferentially down-regulates T helper type 1-mediated im-
mune responses. Nat. Immunol. 4, 899–906.
Tarek, N., Le Luduec, J.B., Gallagher, M.M., Zheng, J., Venstrom, J.M.,
Chamberlain, E., Modak, S., Heller, G., Dupont, B., Cheung, N.K., et al.
(2012). Unlicensed NK cells target neuroblastoma following anti-GD2 antibody
treatment. J. Clin. Invest. 122, 3260–3270.
Tentler, J.J., Tan, A.C., Weekes, C.D., Jimeno, A., Leong, S., Pitts, T.M.,
Arcaroli, J.J., Messersmith, W.A., and Eckhardt, S.G. (2012). Patient-derived
tumour xenografts as models for oncology drug development. Nat. Rev.
Clin. Oncol. 9, 338–350.
Ueno, T., Yeung, M.Y., McGrath, M., Yang, S., Zaman, N., Snawder, B.,
Padera, R.F., Magee, C.N., Gorbatov, R., Hashiguchi, M., et al. (2012). IntactB7-H3 signaling promotes allograft prolongation through preferential suppres-
sion of Th1 effector responses. Eur. J. Immunol. 42, 2343–2353.
Veenstra, R.G., Flynn, R., Kreymborg, K., McDonald-Hyman, C., Saha, A.,
Taylor, P.A., Osborn, M.J., Panoskaltsis-Mortari, A., Schmitt-Graeff, A.,
Lieberknect, E., et al. (2015). B7-H3 expression in donor T cells and host cells
negatively regulates acute graft-versus-host disease lethality. Blood 125,
3335–3346.
Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J.,
Heslop, H.E., Rooney, C.M., Brenner, M.K., et al. (2006). T lymphocytes redir-
ected against the kappa light chain of human immunoglobulin efficiently kill
mature B lymphocyte-derived malignant cells. Blood 108, 3890–3897.
Vigdorovich, V., Ramagopal, U.A., Lazar-Molnar, E., Sylvestre, E., Lee, J.S.,
Hofmeyer, K.A., Zang, X., Nathenson, S.G., and Almo, S.C. (2013). Structure
and T cell inhibition properties of B7 family member, B7-H3. Structure 21,
707–717.
Walker, A.J., Majzner, R.G., Zhang, L., Wanhainen, K., Long, A.H., Nguyen,
S.M., Lopomo, P., Vigny, M., Fry, T.J., Orentas, R.J., et al. (2017). Tumor anti-
gen and receptor densities regulate efficacy of a chimeric antigen receptor tar-
geting anaplastic lymphoma kinase. Mol. Ther. 25, 2189–2201.
Xu, Y., Zhang, M., Ramos, C.A., Durett, A., Liu, E., Dakhova, O., Liu, H.,
Creighton, C.J., Gee, A.P., Heslop, H.E., et al. (2014). Closely related T-mem-
ory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are
preserved by IL-7 and IL-15. Blood 123, 3750–3759.
Yamato, I., Sho, M., Nomi, T., Akahori, T., Shimada, K., Hotta, K., Kanehiro, H.,
Konishi, N., Yagita, H., and Nakajima, Y. (2009). Clinical importance of B7-H3
expression in human pancreatic cancer. Br. J. Cancer 101, 1709–1716.
Zang, X., Sullivan, P.S., Soslow, R.A.,Waitz, R., Reuter, V.E.,Wilton, A., Thaler,
H.T., Arul, M., Slovin, S.F., Wei, J., et al. (2010). Tumor associated endothelial
expression of B7-H3 predicts survival in ovarian carcinomas. Mod. Pathol. 23,
1104–1112.
Zang, X., Thompson, R.H., Al-Ahmadie, H.A., Serio, A.M., Reuter, V.E.,
Eastham, J.A., Scardino, P.T., Sharma, P., and Allison, J.P. (2007). B7-H3
and B7x are highly expressed in human prostate cancer and associated with
disease spread and poor outcome. Proc. Natl. Acad. Sci. U S A 104,
19458–19463.
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
B7-H3-BV421 (clone 7-517) BD Biosciences Cat# 565829,
RRID:AB_2739369
CD3-APC-H7 (clone SK7) BD Biosciences Cat# 560176,
RRID:AB_1645475
CD4-BV421 (clone RPA-T4) BD Biosciences Cat# 562424,
RRID:AB_11154417
CD4-BV510 (clone SK3) BD Biosciences Cat# 562970,
RRID:AB_2744424
CD4-BV711 (clone SK3) BD Biosciences Cat# 563028,
RRID:AB_2737961
CD8-FITC (clone SK1) BD Biosciences Cat# 347313, RRID:AB_400279
CD8-Alexa Fluor 700 (clone RPA-T8) BD Biosciences Cat# 561453,
RRID:AB_10643765
CD8-APC (clone SK1) BD Biosciences Cat# 340584, RRID:AB_400526
CD19-APC (clone HIB19) BD Biosciences Cat# 555415, RRID:AB_398597
CD19-PE (clone SJ25C1) BD Biosciences Cat# 340364, RRID:AB_400018
CD27-BV421 (clone M-T271) BD Biosciences Cat# 562513,
RRID:AB_11153497
CD28-APC (clone CD28.2) BD Biosciences Cat# 559770, RRID:AB_398666
CD28-PE-Cy7 (clone CD28.2) BD Biosciences Cat# 560684,
RRID:AB_1727459
CD45-PE (clone HI30) BD Biosciences Cat# 555483, RRID:AB_395875
CD45RA-BV605 (clone HI100) BD Biosciences Cat# 562886,
RRID:AB_2737865
CD45RA-PE (clone HI100) BD Biosciences Cat# 555489, RRID:AB_395880
CD62L-BV605 (clone DREG-56) BD Biosciences Cat# 562719,
RRID:AB_2744441
CCR7-FITC (clone 150503) BD Biosciences Cat# 561271,
RRID:AB_10561679
PD-1-PE-Cy7 (clone EH12.1) BD Biosciences Cat# 561272,
RRID:AB_10611585
PD-L1-PE (clone MIH1) BD Biosciences Cat# 557924, RRID:AB_647198
TIM3-BV711 (clone 7D3) BD Biosciences Cat# 565566,
RRID:AB_2744370
mCD3e-APC-Cy7 (clone 145-2C11) BD Biosciences Cat# 557596, RRID:AB_396759
mCD4-PerCP-Cy5.5 (clone RM4-5) BD Biosciences Cat# 550954, RRID:AB_393977
mCD8a-BV510 (clone 53-6.7) BD Biosciences Cat# 563068,
RRID:AB_2687548
mCD11b-APC (clone M1/70) BD Biosciences Cat# 553312, RRID:AB_398535
mCD11c-BV421 (clone HL3) BD Biosciences Cat# 562782,
RRID:AB_2737789
mCD19-FITC (clone 1D3) BD Biosciences Cat# 553785, RRID:AB_395049
mLy-6G-PE (clone 1A8) BD Biosciences Cat# 561104,
RRID:AB_10563079
mNK-1.1-PE-Cy7 (clone PK136) Biolegend Cat# 108714, RRID:AB_389364
mPD-1-PE (clone J43) BD Biosciences Cat# 551892, RRID:AB_394284
Goat anti-mouse Ig-APC (Polyclonal) BD Biosciences Cat# 550826, RRID:AB_398465
(Continued on next page)
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Goat Anti-Mouse IgG-AF647 (Anti-Fab) (Polyclonal) Jackson ImmunoResearch Labs Cat# 115-606-072,
RRID:AB_2338928
Anti-B7-H3 (clone EPNCIR122) Abcam Cat# ab134161,
RRID:AB_2687929
Anti-B7-H3 (clone 376.96) Generated by Dr. Soldano Ferrone
(Imai et al., 1982)
N/A
Anti-m/hCD3 (clone SP7) (for IHC) Novus Biologicals Cat# NB600-1441,
RRID:AB_789102
Anti-CD3 (clone OKT3) Miltenyi Biotec Cat# 130-093-387,
RRID:AB_1036144
Anti-CD28 (clone CD28.2) BD Biosciences Cat# 555725, RRID:AB_396068
Anti-CD19.CAR (clone 233-4A) Generated by the Core Facility at MD Anderson
Cancer Center
N/A
HRP polymer conjugated goat anti-mouse
Ig secondary Ab
Dako Cat# K4000




Human normal tissue array US Biomax FDA903a
Mouse normal tissue array BioChain T6334701-2
Human ovarian cancer tissue array US Biomax FOV401




Chemicals, Peptides, and Recombinant Proteins
2Ig-B7-H3-Fc ACRO Biosystems CAT# B73-H5253-100ug
2Ig-B7-H3-His ACRO Biosystems CAT# B73-H52E2-100ug
4Ig-B7-H3-Fc AdipoGen LifeSciences CAT# CHI-HF-211B7H3B-C100
4Ig-B7-H3-His Novus Biologicals CAT# NBP2-59914-250ug
mB7-H3-Fc ACRO Biosystems CAT# B73-M5255-100ug
mB7-H3-His ACRO Biosystems CAT# B73-M52H4-100ug
2Ig-B7-H3-GFP This paper N/A
Murine GM-CSF PeproTech CAT# 315-03
Human IL-7 PeproTech CAT# 200-07
Human IL-15 PeproTech CAT# 200-15
Normal goat serum Sigma-Aldrich CAT# G9023-10ML
RetroNectin Takara CAT# T100B
GeneJuice Merck Millipore CAT# 70967
Phusion PCR master mix Thermo CAT# F-531
Xylenes Fisher Chemical CAT# X3P-1GAL
10% neutral buffered formalin Fisher Chemical CAT# SF100-4
XenoLight D-Luciferin Perkin Elmer CAT# 122799
4% Paraformaldehyde Solution in PBS Fisher Chemical CAT# AAJ19943K2
30% H2O2 Sigma-Aldrich CAT# 216763-100ML
Critical Commercial Assays kit
Human IFN-gamma ELISA kit R&D systems CAT# DY285B
Human IL-2 ELISA kit R&D systems CAT# DY202
Murine IFN-gamma ELISA kit R&D systems CAT# DY485-05
Murine IL-2 ELISA kit R&D systems CAT# DY402-05
(Continued on next page)
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ELISA substrate reagent pack R&D systems CAT# DY999
DAB substrate kit Cell Signaling technology CAT# 8059S
Experimental Models: Cell Lines
Panc-1 ATCC CAT# CRL-1469
Panc-10.05 ATCC CAT# CRL-2547
Capan-1 ATCC CAT# HTB-79
BxPC-3 ATCC CAT# CRL-1687
AsPC-1 ATCC CAT# CRL-1682
CHLA-255 Gift from Dr. Metelitsa, Baylor College of
Medicine, Houston TX
N/A
LAN-1 Gift from Dr. Brenner, Baylor College of
Medicine, Houston TX
N/A
IMR-32 ATCC CAT# CCL-127
SKNLP Gift from Dr. Brenner, Baylor College of
Medicine, Houston TX
N/A
KPC-4662 Isolated by Dr. Vonderheide’s lab (Bayne
et al., 2012; Hingorani et al., 2005)
N/A
SW626 ATCC CAT# HTB-78
SK-OV-3 ATCC CAT# HTB-77
CaoV-3 ATCC CAT# HTB-75
Raji ATCC CAT# CCL-86
PDAC-2 Isolated by Dr. Cristina Ferrone, Massachusetts
General Hospital, Boston, MA
N/A
PDAC-3 Isolated by Dr. Cristina Ferrone, Massachusetts
General Hospital, Boston, MA
N/A
PDAC-6 Isolated by Dr. Cristina Ferrone, Massachusetts









SFG.2Ig-B7-H3 This paper N/A
SFG.4Ig-B7-H3 This paper N/A
SFG.mB7-H3 This paper N/A
SFG.2Ig-B7-H3-GFP This paper N/A
mB7-H3 cDNA clone InVivogene Cat# puno1-mb7h3
SFG.B7-H3.CAR-28z This paper N/A
SFG.B7-H3.CAR-4-1BBz This paper N/A
SFG.mCD19.CAR This paper N/A
SFG.mB7-H3.CAR This paper N/A
Software and Algorithms
Flowjo v10. Flowjo N/A
GraphPad Prism GraphPad Software Inc. N/A
Living Image v4.5.2 (IVIS imaging) Perkin Elmer N/A
Aperio color deconvolution v9 Leica Biosystems N/A
Other
Counting beads Invitrogen Cat# C36950
Zombie Aqua Fixable Viability Kit BioLegend Cat# 423102
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Gianpietro
Dotti, Email: gdotti@med.unc.edu.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and Cell Culture
Human pancreatic (PDAC) tumor cell lines Panc-1 (Source: male), BxPC-3 (Source: female), Panc-10.05 (Source: male), Capan-1
(Source: male) and AsPC-1 (Source: female), human ovarian cancer (OC) cell lines SW626 (Source: female), SK-OV-3 (Source: fe-
male) and CaoV-3 (Source: female), and human neuroblastoma (NB) cell line IMR-32 (Source: male) were purchased from American
Type Culture Collection (ATCC). Human NB cell lines CHLA-255 (Source: unknown, initially derived from a metastatic lesion in the
brain in a patient with recurrent disease at Children’s Hospital Los Angeles (Sohara et al., 2003)) and FFluc-CHLA-255 are gifts
from Dr. Metelitsa at Baylor College of Medicine (Houston TX) (Song et al., 2009), and LAN-1 (Source: male) and SKNLP (Source:
unknown, initially derived from a patient with NB treated at Memorial Sloan-Kettering Cancer Center (Tarek et al., 2012)) are gifts
from Dr. Brenner at Baylor College of Medicine (Houston TX) (Tarek et al., 2012). Human PDAC cell lines PDAC2 (Source: male),
PDAC3 (Source: female), and PDAC6 (Source: male) were established at Dana-Farber Cancer Institute and Massachusetts General
Hospital by Dr Cristina Ferrone from ascites of PDAC patients. Murine pancreatic tumor cell line KPC-4662 was a gift from Dr. Yuliya
Pylayeva-Gupta, originally obtained fromDr. Vonderheide (University of Pennsylvania) (Bayne et al., 2012; Hingorani et al., 2005). The
tumor cell line SK-OV-3 was selected three times in vivo in NSG mice to obtain a very aggressive clone. Capan-1 cell lines
were cultured in IMDM (Gibco, Invitrogen) supplemented with 10% FBS (Sigma), 2 mM GlutaMax (Gibco). BxPC-3, Panc-10.05,
PDAC-2, PDAC-3, PDAC-6, KPC-4662, SW626, CHLA-255, IMR-32, LAN-1 and SKNLP were cultured in RPMI1640 (Gibco) supple-
mented with 10% FBS and 2 mM GlutaMax. AsPC-1 was cultured in RPMI1640 (Gibco) supplemented with 10% FBS, 2 mM
GlutaMax and 1mM Sodium pyruvate (Gibco). Panc-1 and Caov-3 cells were cultured in DMEM (GIBCO) supplemented with 10%
FBS and 2 mM GlutaMax. SK-OV-3 was cultured in McCoy’s medium supplemented with 10% FBS and 2 mM GlutaMax. Penicillin
(100 unit/mL) (Gibco) and streptomycin (100 mg/mL) (Gibco) were added to cell culture media. Cells were maintained in a humidified
atmosphere containing 5%CO2 at 37
C. Panc-1, Panc-10.05, BxPC-3, Capan-1, AsPC-1, PDAC-2, PDAC-3 and PDAC-6 cells were
transduced with a retroviral vector encoding GFP. The human B-cell lymphoma Raji (Source: male) cell line obtained from ATCCwas
transduced with retroviral vectors encoding either human or murine B7-H3, and sorted to generate single cell clones. The murine
pancreatic tumor cell line KPC-4662 was transduced with a retroviral vector encoding the murine B7-H3. Panc-1, BxPC-3 and
SK-OV-3 cells were also transduced with a retroviral vector encoding the GFP-Firefly-Luciferase (GFP-FFluc) gene (Vera et al.,
2006). All cell lines were mycoplasma free, and validated by flow cytometry for surface markers and functional readouts as needed.
Human and Mouse Tissue Samples
Frozen normal human tissue microarrays (TMA) and human ovarian cancer TMA were purchased from US Biomax (Rockville, USA).
Frozen normal mouse TMA were purchased from BioChain Institute Inc. (Newark, USA). The use of this material does not require
Institutional Review Board (IRB) approval. Frozen PDAC specimens were obtained from the Tissue Procurement Facility at the Line-
berger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill (UNC), and the specimens were collected
under an Institutional Review Board (IRB) approved protocol (IRB 90–0573) with obtained informed consent. These deidentified
samples are distributed by the facility under non-human subject study IRB approval. For the PDAC-PDX, fresh tumor samples
from deidentified PDAC patients were obtained under protocols approved by IRB at UNC with obtained informed consent. All
patient-derived tissues were stained with hematoxylin and eosin to confirm histology. Tumors were implanted orthotopically into
the pancreas of 6 - 8 weeks old female NSG mice under protocols approved by the Institutional Animal Care and Use Committee
at UNC.
In Vivo Mouse Studies
Male and female 4 - 6 weeks old NSG mice were purchased from the Animal Core Facility at UNC. Male and female 4 - 6 weeks old
C57BL/6J mice were purchased from The Jackson Laboratory. All the mice were housed in the Animal Core Facility at UNC. All
mouse experiments were performed in accordance with UNC Animal Husbandry and Institutional Animal Care and Use Committee
(IACUC) guidelines and were approved by UNC IACUC.
METHOD DETAILS
Plasmid Construction and Retrovirus Production
The full-length human 2Ig-B7-H3 (GenBank: NM_001329628) and 4Ig-B7-H3 (GenBank: NM_001024736) genes were amplified by
PCR from cDNA obtained from the Panc-1 cell line, and cloned into the retroviral vector SFG. Murine B7-H3 (GenBank: NM_133983)
was amplified by PCR from a plasmid obtained from InVivogene (San Diego, CA), and cloned into the retroviral vector SFG. The 2Ig-
B7-H3-GFP fusion protein was generated by fusing the coding region of 2Ig-B7-H3 extracellular domain (1-248 amino acids) with the
GFP gene by fusion PCR, and cloned into the retroviral vector SFG. The variable regions of the heavy and light chains of the 376.96
mAb were cloned from the 376.96 mouse hybridoma and then cloned as a scFv fragment into previously validated CAR formats that 
include the human CD8a hinge and transmembrane domain, CD28 or 4-1BB intracellular costimulatory domains and CD3z intracel-
lular signaling domain. The B7-H3.CAR cassettes were cloned into the retroviral vector SFG. For the murine version of the B7-
H3.CAR (mB7-H3.CAR), human CD8a, CD28 and CD3z were replaced by murine CD28 and CD3z. The scFv specific for murine 
CD19 was previously reported (Kochenderfer et al., 2010).
Retrovirus Preparation
Retroviral supernatants used for the transduction of human T cells were prepared as previously described (Vera et al., 2006). Briefly, 
2 3 106 293T cells were seeded in 10 cm cell culture dish and transfected with the plasmid mixture of the retroviral vector, the Peg-
Pam-e plasmid encoding MoMLV gag-pol, and the RDF plasmid encoding the RD114 envelope, using the GeneJuice transfection 
reagent (Merck Millipore), according to the manufacturer’s instruction. Similarly, retroviral supernatant used for the transduction 
of murine T cells was generated by cotransfecting 293T cells with the retroviral vector and the pCL-Eco plasmid that encodes 
gag/pol/env using the GeneJuice transfection reagent. Supernatant containing the retrovirus was collected 48 and 72 hours after 
transfection, and filtered with 0.45 mm filters.
Preparation of the 2Ig-B7-H3-GFP Fusion Protein for the T Cell Staining
The retroviral supernatant encoding 2Ig-B7-H3-GFP was generated using the above described retrovirus supernatant preparation 
procedure. The viral supernatant was used to stably transduce 293T cells. The 2Ig-B7-H3-GFP expressing 293T cells were seeded 
in 10 cm cell culture dishes (5 3 106 cells/dish) and the supernatant containing the 2Ig-B7-H3-GFP fusion protein was collected at 48 
hours, filtered with 0.22 mm filter and used for the staining of the B7-H3.CAR-Ts (300 mL/sample) to detect CAR expression.
Transduction and Expansion of Human T Cells
Buffy coats from healthy donors were purchased from the Gulf Coast Regional Blood Center, Houston, TX. Peripheral blood mono-
nuclear cells (PBMCs) isolated with Lymphoprep density separation (Fresenius Kabi Norge) were activated on plates coated with 
1 mg/mL CD3 (Miltenyi Biotec) and 1 mg/mL CD28 (BD Biosciences) agonistic mAbs. On day 2, T lymphocytes were transduced 
with retroviral supernatants using retronectin-coated plates (Takara Bio Inc., Shiga, Japan). Briefly, non-tissue culture treated 
24-well plates are coated overnight with 7 mg/mL retronectin in the cold room, washed once with 1 mL medium, coated with 
1 mL of the retroviral supernatant per well and centrifuged at 2000 g for 90 min. After removal of the supernatant, 5 3 105 activated 
T cells are plated, and centrifuged at 1000 g for 10 min. Three days later, T cells are collected and expanded in complete medium 
(45% RPMI-1640 and 45% Click’s medium (Irvine Scientific), 10% FBS (Hyclone), 2 mM GlutaMAX, 100 unit/mL of Penicillin and 
100 mg/mL of streptomycin) with IL-7 (10 ng/mL; PeproTech) and IL-15 (5 ng/mL; PeproTech), changing medium every 2 - 3 days 
(Xu et al., 2014). On day 12 - 14, cells are collected for in vitro and in vivo experiments. T cells were cultured in IL-7/IL-15 depleted 
medium for two days prior to being used in in vitro functional assays.
Generation of Murine CAR-T Cells
Murine CD4+ and CD8+ T cells were selected by CD4 and CD8 magnetic Microbeads (Miltenyi Biotec) from splenocytes obtained 
from C57BL/6J mice and stimulated on plates coated with 1 mg/mL mCD3 (eBioscience) and 1 mg/mL mCD28 mAbs (eBioscience) 
for 24 hours. Activated murine T lymphocytes were transduced with retroviral supernatants using retronectin-coated plates (Takara 
Bio Inc., Shiga, Japan) with the same protocol used to transduce human T cells. After removal from the retronectin plates, T cells were 
expanded in complete medium (RPMI-1640 (Gibco), 10% FBS (Hyclone), 2mM GlutaMAX, 100 mM b-mercaptoethanol, 100 unit/mL 
of Penicillin and 100 mg/mL of streptomycin) with IL-7 (10 ng/mL) and IL-15 (5 ng/mL) changing medium every 2 days. On day 6 - 7, 
T cells were collected and used for functional assays in vitro and in vivo.
Immunohistochemistry and Tissue Histopathology
Frozen PDAC specimens were sectioned by the Histology Research Core Facility at UNC. Slides were dried for 30 minutes at room 
temperature, and fixed in 4% PFA in PBS for 15 min, blocked with 3% H2O2 (Sigma) in distilled water for 20 minutes, then blocked 
with 1% BSA and 10% normal goat serum (Sigma) in PBS for 1 hour at room temperature. Slides were stained with the primary Ab at 
4C overnight. Normal human TMA and tumor tissues were stained with the B7-H3 mAb (clone 376.96, 1:1000 dilution, final concen-
tration 1 mg/mL.)(Imai et al., 1982). Murine normal TMA and tumor tissues were stained with the B7-H3 EPNCIR122 mAb (Abcam, 
Cambridge, USA; 1:500 dilution, final concentration 1.4mg/mL.) that recognizes both human and murine B7-H3 (Seaman et al., 
2017). HRP polymer conjugated goat anti-mouse secondary Ab (Dako, code K4000, 1:8 dilution at 25C for 1.5 hours) was used 
for human TMA and tumor tissues, while the goat anti-rabbit secondary Ab (Dako, code K4002, 1:8 dilution at 25C for 1.5 hours) 
was used for murine TMA and tumor tissues. Slides were developed using DAB chromogen (Cell signaling), counterstained with 
CAT hematoxylin (Biocare medical), dehydrated in ethanol, and cleared in xylene (Fisher chemical). Cover slips were added using 
histological mounting medium (Fisher, toluene solution). Stained TMA slides were digitally imaged at 203 objective using the Aperio 
ScanScope XT (Leica). TMA slides were de-arrayed to visualize individual cores and each core was visually inspected. Folded tissues 
were excluded from the analysis using a negative pen, and all other artifacts were automatically excluded with the Aperio Genie soft-
ware. The B7-H3 positive score was measured using Aperio membrane v9 (cell quantification) algorithm. Percentage of positive cells 
obtained with this algorithm at each intensity level (negative, low, medium, high) were used to calculate the H-Score using the
formula: H-Score = (% at 1+) * 1 + (% at 2+) * 2 + (% at 3+) * 3. The Aperio color deconvolution v9 algorithm with the Genie classifier
was also applied to calculate the area and intensity of the positive stain and generate a Score (0-300). For the CD3 staining, formalin
fixed and paraffin embedded tumor tissues were cut into 5 mmsections by the Histology Research Core Facility at UNC. The sections
were deparaffinized and placed in the antigen retrieval buffer (Thermo Scientific, TA-135-HBL). Heat-induced epitope retrieval was
performed using a decloaking chamber for 30 seconds at 120C followed by 10 seconds at 90C, then blocking with 3% H2O2 in
distilled water for 20 minutes and 10% normal goat serum in TBS for 1 hour at room temperature. Slides were incubated with the
CD3 Ab (1:250 dilution; Novus Bio, NB600-1441) overnight at 4C and biotinylated goat anti-rabbit IgG secondary Ab (1:500 dilution,
Jackson ImmunoResearch, 111-065-144) for 1 hour at room temperature. Staining was visualized using a Vectastain ABC Elite Kit
(1:50 dilution, Vector Labs, PK-6100) followed by diaminobenzidine (DAB, Cell signaling). Stained slides were digitally scanned at
203magnification using the Aperio ScanScope-XT (Aperio Technologies, Vista, CA), and the digital images were analyzed using Tis-
sue Studio software (Tissue Studio version 2.7 with Tissue Studio Library version 4.4.2; Definiens Inc., Munich, Germany). Specif-
ically, Tissue Studio’s Nuclei and Cell Simulation Algorithm was used to detect and enumerate cells that were positive and negative
for murine CD3 signal. Positive cell density = the number of positive cells per mm2 area analyzed. Tissue sections and hematoxylin
and eosin staining for animal tissue histopathology was performed by the Animal Histopathology & Laboratory Medicine Core at
UNC, and scored by a mouse pathologist.
ELISA
T cells (1 x 105 or 5 x 105) were co-cultured with tumor cells (5 x 105) in 24-well plates without the addition of exogenous cytokines.
After 24 hours, supernatant was collected and cytokines (IFNg and IL-2) were measured in duplicate using specific ELISA kits (R&D
system) following manufacturer’s instructions.
Flow Cytometry
We performed flow cytometry using Abs specific to human CD3, CD4, CD8, CD19, CD27, CD28, CD45, CD45RA, CD62L, CCR7,
B7-H3, PD-1, PD-L1 and TIM3, and murine CD3, CD4, CD8, CD11b, CD11c, CD19, PD-1, Ly-6G and NK1.1 (from BD bioscience
and Biolegend) conjugated with BV421, BV510, BV605, BV711, FITC, AF488, PerCP-cy5.5, PE, PE-cy7, APC and APC-cy7 fluoro-
chromes. Expression of human B7-H3 in tumor cell lines was assessed with the 376.96 mAb and confirmed with another B7-H3 Ab
clone 7-517 (BD bioscience) (Imai et al., 1982). Expression of murine B7-H3 in BMDCs was assessed with the 376.96 Ab and the
B7-H3 Ab clone EPNCIR122 (Abcam) (Seaman et al., 2017). Expression of the B7-H3.CARs was detected using the fusion protein
2Ig-B7-H3-GFP or the Fab Ab (Jackson ImmunoResearch Laboratories INC.). Samples were acquired with BD FACSCanto II or
BD FACSFortessa using the BD Diva software (BD Biosciences). For each sample a minimum of 10,000 events were acquired
and data were analyzed using Flowjo 10.
Co-culture Experiments
Tumor cells were seeded in 24-well plates at a concentration of 53 105 cells/well. T cells were added to the culture at different ratios
(E:T of 1:1; 1:5, or 1:10) without the addition of exogenous cytokines. Cells were analyzed at day 5 - 7 to measure residual tumor cells
and T cells by FACS. Dead cells were gated out by Zombie Aqua Dye (Biolegend) staining while T cells were identified by the expres-
sion of CD3 and tumor cells by the expression of GFP (PDAC, OC and NB cell lines), or CD19 (Raji, Raji-2IgB7-H3, Raji-4IgB7-H3 and
Raji-mB7H3) or mB7-H3 (KPC-4662-mB7-H3) (Hoyos et al., 2010; Vera et al., 2006).
Proliferation Assay
T cells were labeled with 1.5 mM carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen) and plated with tumor cells at an
E:T ratio of 1:1. CFSE dilution was measured on gated T cells on day 5 using flow cytometry (Hoyos et al., 2010).
Xenogeneic Mouse Models
For the PDACorthotopicmodel, FFluc-Panc-1 (23 105) or FFluc-BxPC-3 (13 105) tumor cells were suspended in 25 mLDPBS,mixed
with 25 mLMatrigel (Corning) and surgically implanted into the pancreas of 8 - 10weeks oldmalemice using 28-gauge needle. Briefly,
an incision was performed in the left flank and PDAC tumor cells were injected using a 28-gauge needle into the tail of the pancreas.
Thewoundwas closed in two layers, with running 4-0 Vicryl, and polypropylene sutures for the skin. Twelve or 28 days after tumor cell
inoculation, CD19.CAR-28z (control), B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts were injected intravenously via tail injection (i.v.)
(1 3 107 cells/mouse). For the PDAC metastatic model, 8 - 10 weeks old male or female mice were injected i.v. with FFluc-
Panc-1 (1 3 106) tumor cells. On day 14 after tumor cell inoculation, CD19.CAR-28z-Ts, B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-
Ts were injected i.v. (1 3 107 cells/mouse). For the Panc-1 re-challenge model, 6 weeks old female mice were injected i.v. with
FFluc-Panc-1 (1 3 106) tumor cells. On day 14 after tumor cell inoculation, CD19.CAR-28z-Ts, B7-H3.CAR-28z-Ts or B7-
H3.CAR-BBz-Ts were injected i.v. (1 3 107 cells/mouse). Twenty-eight days after CAR-Ts treatment, mice were re-challenged
with 1 3 106 FFluc-Panc-1 tumor cells and followed for three weeks. Mice received another tumor re-challenged with 1 3 106
FFluc-Panc-1 tumor cells on day 49 and 63 after CAR-Ts treatment. For the PDAC-PDX pancreatic orthotopic xenograft model,
human PDAC tumor fragments were orthotopically implanted into the pancreas of female NSG mice. Twenty-one days after
tumor engraftment, CD19.CAR-28z-Ts, B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts (1 3 107/mouse) were injected i.v.. Tumor
size was monitored by ultrasound (US) imaging on day -4, 15 and 31 after T cell infusion. Tumor volume was calculated by the
formula: volume = 0.52 3 length 3 width2. For the NB metastatic model, 6 - 8 weeks old male or female NSG mice were injected 
i.v. with the tumor cell line FFluc-CHLA-255 (2 3 106 cells/mouse). Fourteen days after tumor inoculation, CD19.CAR-28z-Ts 
(5 3 106 cells/mouse) or B7-H3.CAR-28z-Ts (2 3 106 or 5 3 106 cells/mouse) were injected i.v.. For the OC xenograft model, the 
human OC cell line FFluc-SK-OV-3 (5 3 105 cells/mouse) suspended in matrigel was inoculated intraperitoneally (i.p.) into 6 - 8 weeks 
old female NSG mice. Fourteen days after tumor inoculation, CD19.CAR-28z-Ts, B7-H3.CAR-28z-Ts or B7-H3.CAR-BBz-Ts were 
injected either i.p or i.v. (5 3 106 cells/mouse). No randomization was used. Investigators were not blinded, but mice were matched 
based on the tumor bioluminescence or tumor volume measured by US imaging before assignment to control or treatment groups. 
Tumor growth was monitored by bioluminescence imaging using IVIS lumina II in vivo imaging system (PerkinElmer) or by US imaging 
in the PDAC-PDX model. Mice were euthanized when signs of discomfort were detected by the investigators or as recommended by 
the veterinarian who monitored the mice three times a week, or when luciferase signal reached 1 3 1011 photons per second per cm2. 
Tumor specimens were collected and snap frozen for immunohistochemistry to detect B7-H3 and CD3 expression.
Generation of Murine Bone Marrow Derived Dendritic Cells (BMDCs)
Femur bone was removed from C57BL/6J mice and sterilized by soaking in 70% ethanol and then washed three times with phos-
phate buffer solution (PBS). Bone marrow cells were flushed out using PBS (Matheu et al., 2008). Red blood cells were removed 
by red blood cell lysis buffer. Mononuclear cells were seeded (1 3 106 cells per well) in non-tissue culture treated 24-well plates 
and cultured with RPMI1640 medium (Gibco), 10% FBS (Hyclone), 2mM GlutaMAX, 100 mM b-mercaptoethanol, 100 unit/mL of peni-
cillin and 100 mg/mL of streptomycin) in the presence of murine GM-CSF (20 ng/mL; PeproTech) and changing medium every 2 days. 
At day 5, cells were harvested and treated with 100 ng/mL lipopolysaccharide (LPS) (Invivogen). Two days later, BMDCs were har-
vested and assessed for the expression of CD11c and mB7-H3 by flow cytometry. BMDCs were then used in co-culture experiments 
with murine T cells.
Evaluate Toxicity of mB7-H3.CAR-Ts in C57BL/6J Immunocompetent Mice
Six weeks old male C57BL/6J mice were irradiated with 400 cGy to create a lymphodepleted environment to favor the expansion of 
adoptively transferred syngeneic T cells. Two days post-irradiation, mice were infused i.v. with syngeneic control non-transduced 
T cells (NT), mCD19.CAR-Ts or mB7-H3.CAR-Ts (1 3 107/mouse by i.v. injection). Five days after T cell infusion, we assessed the 
blood cell composition by flow cytometry and counting beads. Mice were then euthanized 15 - 16 days post T-cell infusion. Immune 
cell composition of the blood, spleen, bone marrow and lymph nodes was assessed by flow cytometry and counting beads. Tissues 
were also collected and evaluated by hematoxylin and eosin staining. A board-certified anatomic veterinary pathologist analyzed the 
slides at the Translational Pathology Laboratory at UNC. In parallel experiments, 6 - 8 weeks old C57BL/6J male mice received syn-
geneic NT, mCD29.CAR-Ts and mB7-H3.CAR-Ts (1 3 107/mouse) without irradiation.
Murine PDAC Orthotopic Model in C57BL/6J Mice
The murine PDAC tumor cell line KPC-4662 was engineered to express mB7-H3 at similar level as observed in human PDAC, and 
implanted into the pancreas of six weeks old C57BL/6J female mice by surgery (1 3 105 cells/mouse). Seventeen days post-tumor 
cell implantation, mice were irradiated with 400 cGy to create a lymphodepleted environment. Two days post-irradiation, mice were 
infused i.v. with syngeneic control NT or mB7-H3.CAR-Ts (1 3 107 cells/mouse). Tumor growth was monitored by US imaging. Mice 
were euthanized at day 33 - 34 post T-cell infusion. Immune cell composition of the blood, spleen, bone marrow and lymph nodes 
was assessed by flow cytometry and counting beads and tissues analyzed by immunohistochemistry using hematoxylin and eosin 
staining.
Measurement of the Binding Affinity of the 376.96 mAb to Human and Murine B7-H3
The binding affinity of the 376.96 mAb for human and murine B7-H3 was determined by Microscale Thermophoresis (MST). The h4Ig-
B7-H3-His (Novus Bio, Littleton, USA), h2Ig-B7-H3-His (ACRO bio, Newark, USA) and mB7-H3-His (ACRO bio, Newark, USA) pro-
teins were fluorescently labeled using RED-tris-NTA dye (NanoTemper Technology, Munich, Germany). Ten microliters of the labeled 
protein (50 nM) was mixed with 10 mL of the 376.96 mAb (concentration varying between 1 nM and 10 mM) in PBST buffer (PBS with 
0.05% Tween 20) and loaded into 16 standard treated capillaries. The samples were excited by a Red LED at 50% power and the 
thermophoresis of each sample was measured at 60% MST power on Monolith NT.115 (NanoTemper Technology, Munich, 
Germany).
Stimulation of B7-H3.CAR-Ts with Plate-Bound B7-H3-Fc Fusion Proteins
Non-tissue culture treated 96-well plates were coated with h4Ig-B7-H3-Fc (AdipoGen Cor., Liestal, Switzerland), h2Ig-B7-H3-Fc 
(ACRO bio, Newark, USA) and mB7-H3-Fc (ACRO bio, Newark, USA) proteins in 100 mL PBS (concentration ranging between 
10 nM and 200 nM) for 24 hours at 4C. Plates were washed three times with DPBS, and 2 3 105 B7-H3.CAR-28z-Ts in 200 mL of  
T cell medium were added to each well. Twenty four hours later, supernatants were collected and IFNg was measured by ELISA.
Measurement of the Copy Numbers of mB7-H3.CAR
Mice inoculated with mB7-H3-CAR-Ts were sacrificed on day 33 - 34 post CAR-Ts treatment, and spleens and tumors were har-
vested. Genomic DNA was extracted (Qiagen), and quantitative PCR (qPCR) performed using primers and probes (TaqMan TAMRA
from Applied Biosystems, Thermo Fisher Scientific) spanning the scFv. qPCR was performed using the QuantStudio 6 Flex (Applied
Biosystems, Thermo Fisher Scientific). Standard curves were prepared using serial dilutions of the mB7-H3.CAR plasmid. The copy
number of unknown samples was interpolated from the standard curves using GraphPad Prism Software (La Jolla, CA).
QUANTIFICATION AND STATISTICAL ANALYSIS
The unpaired and nonparametricMannWhitney test with two tailed p value calculation was used tomeasure differences between two
groups. For multiple group comparisons, one-way ANOVA or two-way ANOVA was used to determine statistically significant differ-
ences between samples. Holm-Sidak test adjusted p value < 0.05 indicates a significant difference.Measurements were summarized
asmean ± SDas noted in the figure legends. Difference between the bioluminescence of tumor and the survival curveswere analyzed
by the Chi-square test using GraphPad Prism v5. Experimental sample numbers (n) are indicated in the figure legends. The statistical
analysis method is also described in the individual figure legends. Graph generation and statistical analyses were performed using
the GraphPad Prism software (GraphPad, La Jolla, CA).
